by Plus Therapeutics | Aug 6, 2025 | LM
Mark your calendars!Date: Thursday, August 14, 2025Time: 6:15 PM ESTLocation: Baltimore Waterfront Marriott, Baltimore, MD We are proud to invite you to a compelling educational symposium at the 2025 SNO/ASCO CNS Metastases Conference, where leading voices in...
by Plus Therapeutics | Aug 1, 2025 | LM
Today, on World Lung Cancer Day, we pause to recognize the strength of patients and survivors and to reflect on the critical need for continued research and innovation in lung cancer care. This annual observance shines a spotlight on the millions of people affected by...
by Plus Therapeutics | Jul 30, 2025 | Uncategorized
In a recent interview with Drug Development & Delivery, Marc Hedrick, M.D., President and CEO of Plus Therapeutics, shared insights into the company’s innovative approach to treating central nervous system (CNS) and solid tumor cancers using targeted...
by Plus Therapeutics | Jul 29, 2025 | LM
Leptomeningeal metastases (LM) remain one of the most challenging complications in neuro-oncology. At Plus Therapeutics, we are committed to changing that. Our ongoing ReSPECT-LM dose-optimization trial is currently evaluating the optimal treatment regimen for...
by Plus Therapeutics | Jul 25, 2025 | Uncategorized
We’re excited to announce that Dr. Andrew Brenner, Principal Investigator for multiple ReSPECT clinical trials, will be going LIVE on Instagram next Tuesday, July 29th at 12:30 PM EST. The conversation will take place on the Game On Glio Podcast Instagram...
Recent Comments